coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Liverpool First PCN, Liverpool (LAD) · Health Inequalities Profile

    PCN U54911 · NHS Cheshire and Merseyside Integrated Care Board · 10 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    45,544

    Registered population

    65.2% aged 18–64

    12.8%

    Aged 65+

    ICB 19.0% · England 17.9%

    21.8%

    Ethnic minority (non-White)

    5.9% Asian · England 9.6%

    78.5%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~28,097

    Core20 residents (est.)

    Resident basis; registered basis ~36,251 · see page 3

    6,362

    Hypertension register

    +3.95% in 3 yrs · England +5.60%

    781

    SMI register

    9.3% of Liverpool (LAD)'s

    1,540

    COPD register

    Reviews -7.95% in 3 yrs

    Forecast to 2030

    7,146

    Hypertension patients, 2030

    +784 on today

    66.5%

    QRISK ≥20% on statins, 2030

    -0.13pp over 3 yrs

    3.1%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -42.6%
    Chronic disease annual reviews fell sharply.

    Heart failure reviews fell 42.6% over 2023 to 2025 to 51.8% (England 78.5%), and asthma reviews fell 14.0%, leaving 816 patients unreviewed.

    62.2%
    Age-five MMR2 and booster coverage lag.

    Age-five MMR2 reaches 62.2% (England 82.8%, 32.8 pp below the 95.0% target) and the 4-in-1 booster is 56.7% (England 80.9%) in Q1 2025/26.

    66.8%
    Cardiovascular lipid and BP control exceed England.

    Lipid-lowering therapy reaches 66.8% for QRISK ≥ 20% (England 63.6%) and 76.6% in CKD (England 70.3%), while hypertension treatment to target is 70.7%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Younger list with 12.8% aged 65+ and 21.8% ethnic minority residents may shape demand

    Liverpool First PCN serves 45,544 registered patients across 10 practices, with lists ranging from 2,177 at GP Practice Riverside (dr Jude) to 9,084 at Dr Jude's Practice - Riverside. Patients aged 0-17 make up 22.1%, above Liverpool (19.8%), the ICB (19.2%) and England (19.6%), whereas those aged 65+ represent 12.8%, below Liverpool (15.6%), the ICB (19.0%) and England (17.9%). Census data for associated resident areas shows 78.2% White residents (Liverpool 84.0%; ICB 93.0%; England 81.1%) and a 21.8% ethnic minority share, including 6.2% Black and 5.9% Asian residents. Ethnicity figures reflect area residents rather than registered patients.

    Age profile

    0–1722.1%
    18–6465.2%
    65+12.8%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White78.2%
    Black6.2%
    Asian5.9%
    Other5.0%
    Mixed4.8%

    Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Liverpool LA)3,0352,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)81.7%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)50.4%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Liverpool LA)1,6521,0219552024/25
    Falls deaths, all ages, per 100,000 (Liverpool LA)27.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 cohort share reaches 78.5% with five practices at 100.0% concentration

    The PCN Core20 cohort is 78.5%, exceeding Liverpool (54.9%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 2.2. Practice estimates sum to 36,251 Core20 patients, whereas resident deciles 1+2 estimate 28,097; these different denominators must be reconciled before targeting. Across the PCN, five practices each show a 100% Core20 share. Meanwhile, Dr Jude's Practice - Riverside records a Core20 cohort of 90.0%, representing 8,177 estimated Core20 patients. Targeting could combine whole-practice outreach for the former group with caseload support for the latter.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Benim100.0% · 5,470 patients
    Abingdon Family100.0% · 3,769 patients
    GP Riverside (dr100.0% · 2,177 patients
    Walton Village100.0% · 3,674 patients
    Bigham Road100.0% · 2,463 patients
    Dr Jude's -90.0% · 8,177 patients
    Yew Tree Centre71.6% · 3,905 patients
    Sandringham56.5% · 3,043 patients
    Stopgate Lane44.9% · 1,527 patients
    Hornspit43.9% · 2,046 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    781

    SMI register

    1.69% recorded prevalence

    523

    Learning disability register

    1.13% recorded prevalence

    24

    Care homes, 1,210 beds

    In the PCN catchment

    10.3%

    Provide unpaid care

    Liverpool (LAD), Census 2021

    Learning disability prevalence is 1.1% (523 patients) and severe mental illness is 1.7% (781 patients), both above Liverpool (0.6% and 1.4%), the ICB (0.6% and 1.1%) and England (0.6% and 1.0%). Catchment care homes total 24 with 1,210 beds, though resident occupancy is unconfirmed. With both inclusion-health registers above England rates, prioritising annual health checks for these cohorts is the key workload to protect.

    Severe mental illness: physical health checks

    Severe mental illness blood pressure check coverage is 77.2% (England 83.4%), falling 3.3 pp over 2023 to 2025 while England rose +4.4 pp. BMI checks fell 0.8 pp (England +5.1 pp) to 81.7%, requiring proactive physical health review.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    6,362

    Hypertension register

    +3.95%

    Register growth, 3 yrs

    Liverpool (LAD) +2.01% · England +5.60%

    +1.35pp

    BP control, under 80

    ≤140/90 · −1.75pp aged 80+

    +784

    More patients by 2030

    Forecast 7,146 (14.84%)

    Hypertension case-finding and control

    Hypertension prevalence is 13.7% (6,362 patients), below England (15.2%), Liverpool (14.0%) and the ICB (16.8%). Patients treated to target reach 70.7% (England 70.3%). However, recent blood pressure readings fell 0.8 pp over 2023 to 2025 (England +3.1 pp) to 86.7% (England 90.0%), blood pressure control at age 80+ fell 1.8 pp (England +1.8 pp) to 80.2% (England 81.2%), and annual heart failure reviews dropped 42.6% (England +8.7%) to 51.8% (England 78.5%). Lower crude prevalence could reflect age profile (12.8% aged 65+), which age-standardisation would test. Monitoring and older-adult control lag national benchmarks, indicating proactive recall should be prioritised.

    Lipids and statins

    Lipid coverage reaches 66.8% for QRISK 20% and over (England 63.6%) and 76.6% in CKD (England 70.3%). However, diabetic primary statin coverage fell 3.6 pp over 2023 to 2025 (England +1.5 pp) to 72.1% (England 73.2%). Diabetic primary statin coverage trails national benchmarks, making a recall audit of eligible patients the immediate priority.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202677,949£1.60£1.71£1.86£124,718
    Cardiovascular (all), 2025108,549£3.69£4.37£3.33£400,546

    For lipid-regulating drugs in 2026, the PCN prescribed 77,949 items at £1.60 per item, below England (£1.86), Liverpool (£1.82), and the ICB (£1.71), spending £20,267 less than at England's unit cost. Unit spend is lower than England, offering headroom to review therapy without exceeding benchmark expenditure.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −13.98%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −1.19%

    Asthma prevalence, PCN 3-yr % change

    COPD recorded prevalence is 3.3% (England 1.9%) across 1,540 patients, but annual reviews fell 8.0% over 2023 to 2025 (England +2.8%) to 77.3%. Asthma reviews fell 10.7 pp or 14.0% (England +2.8 pp or +4.4%) to 65.8%, leaving an estimated 816 patients unreviewed. Prescribing of asthma management items for ages 5-19 reaches 2,586 per 1,000 (England 1,488). Falling review coverage alongside high youth prescribing may reflect follow-up gaps, which practice-level audit would test.

    Cancer register and children's immunisation

    Cancer recorded prevalence is 2.8% across 1,272 patients (England 3.8%). Childhood immunisation coverage in Q1 2025/26 trails national benchmarks across all milestones: 6-in-1 at 12 months is 82.4% (England 91.0%). By age 5, MMR1 reaches 74.0% but MMR2 is 62.2% (England 82.8%, 32.8 pp below the 95.0% target), an 11.8 pp dose difference, while 4-in-1 booster coverage is 56.7% (England 80.9%), which may leave preschool vulnerability, which clinical audit would verify.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months82.4%

    England 91.0%

    6-in-1 complete primary course at 24 months80.2%

    England 92.2%

    MMR dose 1 at 24 months67.6%

    England 88.3%

    MMR dose 2 at age 562.2%

    England 82.8%

    4-in-1 pre-school booster at age 556.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) and up 2.6 pp from 52.8% in 2013 (distance to the 75.0% national ambition by 2028: -19.5 pp; about 2,640 extra early diagnoses required annually). Known-stage coverage was 72.8% (13,490 of 18,522 registered cancers). These ICB figures describe the wider system, not PCN performance. Primary care screening remains low: the PCN achieves 56.5% cervical screening coverage (England 66.8%) and 56.1% breast screening coverage (England 69.9%).

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Liverpool University Hospitals NHS Foundation Trust, 73.2574% of patients met the 62-day referral to treatment standard (distance to the 85.0% standard: -11.7 pp). The trust reached 75.4716% on the 28-day faster diagnosis standard (distance: 0.5 pp against 75.0%) and 90.5077% on the 31-day combined standard (distance to 96.0%: -5.5 pp). Across NHS Cheshire and Merseyside Integrated Care Board, 62-day waits reached 76.232% (distance: -8.8 pp), 28-day diagnosis reached 77.2451% (distance: 2.2 pp), and 31-day treatment was 95.7087% (distance: -0.3 pp). These trust and ICB figures describe the wider system, not PCN performance.

    Pathways within standard (%)LiverpoolMersey and West LancashireWirralCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)75.4772.3974.7177.2579.32
    31-day treatment (96%)90.5195.4692.5395.7192.50
    62-day referral to treatment (85%)73.2677.9677.6576.2371.16
    Diagnostic waits over 6 weeks (%)LiverpoolMersey and West LancashireWirralEngland
    MRI6.4214.041.5421.40
    CT0.7113.081.559.92
    Echocardiography12.5534.885.0728.48
    Colonoscopy33.1418.0432.8130.83
    Gastroscopy44.9918.1717.7329.02
    All 15 DM01 tests11.5021.175.0223.14
    Community services activityLiverpool residentsCheshire and Merseyside ICB
    Care contacts127,380541,280
    Referrals15,67597,150
    Patients with a contact24,970146,240

    Community services (residents of Liverpool), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), adults aged 65 and over accounted for 65.4% of community contacts among Liverpool residents (83,300 of 127,380 total contacts). These borough-level resident figures describe wider system activity rather than PCN-specific contacts.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Inter-practice phone access spans 45.6 pp and good experience varies by 36.2 pp

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Stopgate Lane11144.976.9%66.1%93.1%
    Hornspit12143.971.4%61.1%92.7%
    Walton Village99100.080.5%75.0%91.5%
    Sandringham10756.568.6%74.8%81.5%
    Benim121100.041.1%74.5%69.6%
    Dr Jude's -9490.040.6%83.4%64.8%
    Yew Tree Centre9971.634.9%72.2%62.6%
    Abingdon Family109100.039.4%71.3%61.5%
    GP Riverside (dr80100.036.7%78.2%58.6%
    Bigham Road87100.043.1%61.1%56.9%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNLiverpool (LAD)AssetPCNLiverpool (LAD)
    Care homes (catchment)24 (1,210 beds)n/aSchools (catchment)149n/a
    Children's centres926Places of worship71240
    Libraries417Homelessness support (VCS)n/a1
    Primary schools (LA maintained)2391Primary academies620
    Special schools18

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Asthma annual review and inhaler recall

    Asthma review coverage is 65.8% across 2,383 patients (England 65.7%; Liverpool 64.3%), falling 14.0% (or 10.7 pp) over 2023 to 2025 (England +4.4%; +2.8 pp), leaving 816 unreviewed. For discussion: practices could run structured asthma recall pairing annual review templates with inhaler prescribing checks and after-school slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    SMI physical health check outreach

    Across 781 SMI patients (1.7% prevalence vs England 1.0%), annual blood pressure checks fell 3.3 pp over 2023 to 2025 (England +4.4 pp) to 77.2% (England 83.4%; Liverpool 79.8%). For discussion: practices could audit SMI physical check recording, offer combined outreach appointments and raise data-sharing pathways with system partners. Moderate effort to run.

    Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.

    Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.

    Option 3

    Preschool MMR2 and booster recall

    In Q1 2025/26, age-5 MMR2 coverage is 62.2% (England 82.8%, 32.8 pp below 95.0%, 11.8 pp below MMR1 at 74.0%) and 4-in-1 booster coverage is 56.7% (England 80.9%, 38.3 pp below 95.0%). Moderate effort to run.

    Evidence base: size of the 0–17 cohort: the population for primary immunisation schedule (8, 12 and 16 weeks) and 1-year boosters including MMR dose 1, 2–2.5-year health visiting review, school-based childhood flu vaccination, HPV (12–13), MenACWY and Td/IPV (14) immunisation and new-birth, 6–8 week and 12-month health visiting reviews.

    Policy anchor: Mental health support teams: 77% coverage in 2026/27, 94% by 2028/29, 100% by 2029; Health and Wellbeing Boards must develop neighbourhood health plans for 2027/28 during 2026/27.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Ethnicity recording and access review (p2)WhiteNeighbourhood health framework · Core20PLUS5 approachPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension monitoring and recall (p5)Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Preschool booster and MMR recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Access and patient experience review (p9)GPPS good overall experience of the practice10YHP, hospital to communityPractice
    Option 1 · Asthma annual review and inhaler recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · SMI physical health check outreach (p12)Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Option 3 · Preschool MMR2 and booster recall (p12)Aged 0-17 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15